Last reviewed · How we verify
NCT03668743: PEGREP
Pregnancy Loss Between 15 and 22 Weeks SA Within the Network of Perinatal Pérriodof Western Brittany : Case Control Study PILOT STUDY CA
trial in Miscarriage in Second Trimester in 202 participants. Completed in 1 November 2017.
1 November 2017
Quick facts
| Lead sponsor | University Hospital, Brest |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 202 |
| Start date | 1 June 2017 |
| Primary completion | 1 November 2017 |
| Estimated completion | 1 November 2017 |
| Sites | 2 locations across France |
Conditions studied
- Miscarriage in Second Trimester — all drugs for Miscarriage in Second Trimester →
Sponsor
University Hospital, Brest
Who can join
Adults 18 to 50, female only, with Miscarriage in Second Trimester. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The etiologies and some risk factors for pregnancy loss in the 2nd trimester are described in the literature. However, there are some risk factors that are not studied. The PEGREP study is a retrospective observational case-control study whose main objective is to identify risk factors for pregnancy loss between 15 and 22 weeks. The patients included cases are women who had a pregnancy loss between 15 and 22 SA between 2010 and 2015 and who were listed during the mortality reviews of the perinatal network of Western Brittany. The patient witnesses gave birth at the end of a healthy child in one of the maternity of Western Brittany. Matching 1 case for 1 controls was done on the woman's age, parity and number of fetuses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03668743
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Brest trials
Trials by the same sponsor.
- NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
- NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
- NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
- NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
- NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03668743 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
- Last refreshed: 13 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03668743.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing